Serum apolipoprotein A1: a predictor and prognostic biomarker in acute ischemic stroke

Abstract

Background: The apolipoprotein A1 level is recognized as a better indicator of cardiovascular disease than other cholesterol measures. Objectives: To assess the serum level of ApoA1 in acute stroke patients and correlate it with the degree of vessel stenosis, stroke severity, prognosis, and functional outcome. Patients and methods: We prospectively included 60 patients with first-ever cerebrovascular ischemic stroke, and they were matched with 30 healthy individuals matched in age and sex. Patients' neurological status was assessed via National Institute of Health and Stroke Scale (NIHSS). A venous blood sample was taken within the first 24 h of stroke onset and assayed for ApoA1 level by Human ApoA1 ELISA kit. Results: ApoA1 level could be used to discriminate between cases and controls at a level of 6.2 μg/ml, with 94.9% sensitivity and 86.6% specificity. Furthermore, there is an inverse relationship between the level of ApoA1 and the clinical outcome expressed by NIHSS score and their prognosis after 3 months. Finally, there is an inverse relationship between ApoA1 level and the degree of stenosis whether intracranial or extracranial. Conclusion: ApoA1 level can be used as a predictor of ischemic stroke and as a prognostic tool for those patients with ischemic stroke.

Blood Biomarkers for Triaging Patients for Suspected Stroke: Every Minute Counts

“…Apolipoprotein A1 (APOA1) is a major protein component of the high-density lipoprotein (HDL) and exhibits anti-inflammatory and antioxidant effects, hence playing an important role in the protection of the vascular system against oxidative stress. Studies have shown that the levels of APOA1 decrease in patients with stroke and/or infection [ 30 ]. Similarly, decreased levels of APOA1-UP, as a novel biomarker have been reported to have a high sensitivity (91%) and specificity (97%) for the prediction of IS, nominating it as a promising independent predictor of IS [ 16 ].…”

Identification of the putative causal risk factors and biomarkers of stroke using large-scale genome-wide studies

“…Apolipoprotein A1 (ApoA1) is a protein component of high-density lipoprotein (HDL) and is involved in the transfer of excessive cholesterol from peripheral cells to the liver. Aside from its atheroprotective properties, apoA1 also contains anti-inflammatory and antioxidant properties (53). A previous study found that low amounts of apolipoprotein A1 and high amounts of apolipoprotein B were associated with an increased risk of cerebrovascular stroke and cardiovascular diseases (53)(54)(55)(56).…”

“…Aside from its atheroprotective properties, apoA1 also contains anti-inflammatory and antioxidant properties (53). A previous study found that low amounts of apolipoprotein A1 and high amounts of apolipoprotein B were associated with an increased risk of cerebrovascular stroke and cardiovascular diseases (53)(54)(55)(56). High levels of high-density lipoprotein (HDL) cholesterol significantly reduce the risk of stroke (57).…”